Drugs / MK-4082
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07748351 | Aug → Dec 2026 expected | — | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07697625 | Jul → Sep 2026 overdue | — | Merck Sharp & Dohme LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07388667 | Mar → Sep 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-4082 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07748351 ↗ |
| Route | Oral | “Participants receive escalating doses of oral MK-4082 once daily (QD)” NCT07388667 ↗ |